Compliance. Should you have any questions, please contact Praveen Pabba, Ph.D., ( or

Similar documents
Should you have any questions, please contact Edith Chang, Ph.D., Senior Scientific Liaison ( or

Amlodipine, Valsartan, and Hydrochlorothiazide Tablets

AMOXICILLIN AND CLAVULANIC ACID TABLETS Draft proposal for The International Pharmacopoeia (February 2018)

Streptomycin Sulfate According to USP

MOXIFLOXACIN HYDROCHLORIDE (MOXIFLOXACINI HYDROCHLORIDUM) Draft proposal for The International Pharmacopoeia. (January 2018)

Pharma Research Library. 2013, Vol. 1(1):19-29

Amlodipine and Valsartan Tablets

VALIDATED RP-HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM IN BULK AND PHARMACEUTICAL FORMULATION

C 22 H 28 FNa 2 O 8 Pıı516.4

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF ALISKIREN AND AMLODIPINE IN TABLET DOSAGE FORM

Determination of ofloxacin in bulk drug and pharmaceutical dosage form by high performance liquid chromatography method

Journal of Global Trends in Pharmaceutical Sciences

Tamboli Ashpak Mubarak et al. IRJP 2 (8)

Journal of Applied Pharmaceutical Research ISSN No

Development and validation of a HPLC analytical assay method for amlodipine besylate tablets: A Potent Ca +2 channel blocker

International Journal of Pharmaceutical Research & Analysis

Deptt of Pharma Science SGRR ITS Patel Nagar, Dehradun (UK)

SIMPLE U.V. SPECTROPHOTOMETRIC METHODS FOR THE ESTIMATION OF OFLOXACIN IN PHARMACEUTICAL FORMULATIONS

Development and Validation of Amlodipine Impurities in Amlodipine Tablets Using Design Space Computer Modeling

Development and validation of HPLC method for simultaneous estimation of Amlodipine besylate and Enalapril maleate in solid dosage form

SPECTROPHOTOMETRIC ESTIMATION OF MELOXICAM IN BULK AND ITS PHARMACEUTICAL FORMULATIONS

Isocratic Reverse Phase High Performance Liquid Chromatographic Estimation of Ramipril and Amlodipine in Pharmaceutical Dosage Form

DETERMINATION OF ACTIVE SUBSTANCES IN MULTICOMPONENT VETERINARY PREPARATIONS OF ANTIPARASITIC ACTION BY HPLC METHOD

Determination of gentamicin and related impurities in gentamicin sulfate

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF AMLODIPINE BESYLATE AND IRBESARTAN

Multi-residue Method II for Veterinary Drugs by HPLC (Animal and Fishery Products)

European Journal of Biomedical and Pharmaceutical ISSN Sciences

Development and Validation of RP-HPLC Method for Determination of Related Substances of Medetomidine in Bulk Drug

Ultra-Fast Analysis of Contaminant Residue from Propolis by LC/MS/MS Using SPE

METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF OFLOXACIN AND ORNIDAZOLE IN TABLET DOSAGE FORM BY RP-HPLC

Development and Validation of a RP-HPLC Method for Simultaneous Determination of Levofloxacin and Moxifloxacin in Pharmaceutical Dosage Forms

PO. Vasan, Gandhinagar District, Gujarat, India, 3 Dean at Faculty of Pharmacy, Dharmsinh Desai University, Nadiad, Gujarat, India.

Development and Validation of UV Spectrophotometric Area Under Curve (AUC) method for estimation of Pyrantel Pamoate in Bulk and Tablet Dosage Form

Quantification of Albendazole in Dewormer Formulations in the Kenyan market

Multi-residue Screening of Veterinary Drugs (I) and (II) in Meat According to the Japan Positive List Using Cartridge-based SPE and LC-MS/MS

Specific and Simple HPLC Assay of Ecofriendly Meloxicam in Pharmaceutical Formulations K.T. Mahmood 1, B.Khan 2, M. Ashraf 3 and I. U.

ABSTRACT. Usharani N, Divya K and Ashrtiha VVS. Original Article

Method development and validation for simultaneous estimation of telmisartan and amlodipine by RP-HPLC

Spectrophotometric Method for Simultaneous Estimation of Amlodipine Besylate in Pharmaceutical Formulation

HPLC method for simultaneous determination of Albendazole metabolites in plasma

Determination, Confirmation and Quantitation of Multi-Class Antibiotic Residues in Milk by UHPLC MS/MS

Original Article. Abstract INTRODUCTION

Determination of Acaricides in Korean Honey Bull. Korean Chem. Soc. 2008, Vol. 29, No

Rapid LC-MS/MS Method for the Analysis of Fipronil and Amitraz Insecticides and Associated Metabolites in Egg and Other Poultry Products

New Stability Indicating Method for Quantification of Impurities in Amlodipine and Benazepril Capsules by Validated HPLC

Available online International Journal of Pharmaceutical Research & Allied Sciences, 2016, 5(4):37-44.

Quantification of Chloramphenicol in Chicken Using Xevo TQD with RADAR Technology

Kamepalli Sujana et al. / Journal of Pharmacy Research 2014,8(12), Available online through

Determination of Amlodipine in Rat Plasma by UV Spectroscopy

Chandra Mohan Rao Kota et al INTERNATIONAL JOURNAL OF RESEARCH AND REVIEWS IN PHARMACY AND APPLIED SCIENCES

Stability Indicating Spectrophotometric Method of Amlodipine and Telmisartan in Bulk and Pharmaceutical Dosage Form

Validation of assay indicating method development of meloxicam in bulk and some of its tablet dosage forms by RP-HPLC

Development And Validation Of Methods For Estimation Of Pimobendan In Pharmaceutical Dosage Form

A VALIDATED HPLC-ASSAY FOR THE DETERMINATION OF MELOXICAM IN PRESENCE OF ITS DEGRADATION PRODUCTS

Stability indicating HPLC Method Validation for the Assay of Dexmedetomidine in Dexmedetomidine Hydrochloride Injection

International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.

Pradhan Prasanna Kumar et al. Int. Res. J. Pharm. 2014, 5 (9) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

Stability indicating HPLC method for the simultaneous determination of moxifloxacin and prednisolone in pharmaceutical formulations

ANTIBIOTICS RESIDUES IN HONEY: VALIDATION PROCEDURE HONEY ANALYTICAL METHODS VALIDATION

Screening and Identification Methods for official control of Banned Antibiotics and Growth promoters in Feedingstuffs

SIMPLE HPLC METHOD FOR THE DETERMINATION OF CEFIXIME, OFLOXACIN AND LINEZOLID IN SOLID DOSAGE FORMS

Determination of Total Taurine in Pet Foods by Liquid Chromatography of the Dansyl Derivative: Collaborative Study

Scholars Research Library

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE

A NOVEL STABILITY INDICATING RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF MOXIFLOXACIN AND PREDNISOLONE IN BULK AND THEIR COMBINED DOSAGE FORM

GENTAMICIN SULFATE- gentamicin sulfate solution/ drops Pacific Pharma, Inc GENTAMICIN SULFATE ophthalmic s olution, USP 0.

Public Assessment Report Scientific discussion. Amlodipin Accord (amlodipine besilate)

Detection of residues of quinolones in milk

Agarose for the Separation of GeneAmp PCR Products. Protocol

Development and method validation on stress degradation studies of cefpodoxime proxetil and clavulanic acid in dosage form by hplc method

[ APPLICATION NOTE ] Analysis of Ketamine and Xylazine in Rat Tissues Using the ACQUITY UPLC with 2D Technology APPLICATION BENEFITS INTRODUCTION

Mouse Formulary. The maximum recommended volume of a drug given depends on the route of administration (Formulary for Laboratory Animals, 3 rd ed.

Novel RP-HPLC Method Development and Validation of Meloxicam Suppository

A Validated RP-HPLC Method for Simultaneous Estimation of Nebivolol Hydrochloride and S-Amlodipine Besylate in Tablet Dosage Forms

ANALYTICAL METHOD VALIDATION FOR DETERMINATION OF RELATED SUBSTANCES OF DEXMEDETOMIDINE (IMPURITY-1) IN DEXMEDETOMIDINE HYDROCHLORIDE INJECTION

Augmentin, in Biological Fluids with High-Performance Liquid

20mL, 50mL, 100mL. 20mL, 50mL, 100mL. 20mL, 50mL, 100mL. 20mL, 50mL, 100mL. 20mL, 50mL, 100mL. 50mL, 100mL. 50mL, 100mL.

Prescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):

SCHEDULE P LIFE PERIOD OF DRUGS. [See rule 96] Conditions of storage

Validation of bee4sensor for Honey

Determination of Benzimidazole Residues in Animal Tissue by Ultra High Performance Liquid Chromatography Tandem Mass Spectrometry

Compendial Cancellations for USP36-NF31, First Supplement. <787> SUBVISIBLE PARTICULATE MATTER IN THERAPEUTIC PROTEIN INJECTIONS PF 38(3) Pg.

Veterinary Drug Detection in Pork and Milk

Dosing Your Cat with Azithromycin Pediatric Suspension. By Lorraine Shelton

Analysis of Multiclass Veterinary Drugs in Baby Food by Ultra Fast Chromatography with High Performance Triple Quadrupole Mass Spectrometry

Simultaneous Estimation of Nebivolol hydrochloride and Amlodipine besylate by UV Spectrophotometric Method

Center for Veterinary

SCIENTIFIC DISCUSSION

Agarose Blenders. Code Description Size

Asian Journal of Pharmaceutical Research and Development (An International Peer-Reviewed Journal of Pharmaceutical Research and Development)

Public Assessment Report. Scientific discussion. Xiflodrop 5 mg/ml eye drops, solution. Moxifloxacin hydrochloride DK/H/2221/001/DC

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

Determination of Beta-Lactamase Inactivation of Cephalexin by Validated RP-HPLC Method

SUMMARY OF THE PRODUCT CHARACTERISTICS

Sci Pharm

A reverse phase high performance liquid chromatography method was developed for simultaneous estimation of

A simple and easy method for determination of meloxicam in rat muscle and plasma

For the treatment and prevention of infections caused by:

SUMMARY OF PRODUCT CHARACTERISTICS. Lincomycin (as Lincomycin hydrochloride) Neomycin (as Neomycin sulphate) Excipients Disodium edetate

Sensitive and selective analysis of fipronil residues in eggs using Thermo Scientific GC-MS/MS triple quadrupole technology

Transcription:

Doxycycline Hyclate Delayed-Release Tablets Type of Posting Revision Bulletin Posting Date 28 Jul 2017 Official Date 01 Aug 2017 Expert Committee Chemical Medicines Monographs 1 Reason for Revision Compliance In accordance with the Rules and Procedures of the 2015-2020 Council of Experts, the Chemical Medicines Monographs 1 Expert Committee has revised the Doxycycline Hyclate Delayed-Release Tablets monograph. The purpose of the revision is to add Dissolution Test 5 for a generic product approved by the FDA. The Doxycycline Hyclate Delayed-Release Tablets Revision Bulletin supersedes the currently official monograph. The Revision Bulletin will be incorporated into the First Supplement to USP 41 NF 36. Should you have any questions, please contact Praveen Pabba, Ph.D., (301 816 8540 or pkp@usp.org).

. C Revision Bulletin Official August 1, 2017 Doxycycline 1 Doxycycline Hyclate Delayed-Release Tablets U = nominal concentration of doxycycline in the Sample Acceptance criteria: 90.0% 120.0% PERFORMANCE TESTS DEFINITION Doxycycline Hyclate Delayed-Release Tablets contain an amount of Doxycycline Hyclate equivalent to NLT 90.0% Change to read: and NMT 120.0% of the labeled amount of doxycycline (C 22H 24N 2O 8). DISSOLUTION 711 Test 1: Proceed as directed for Dissolution 711, Procedure, Apparatus 1 and Apparatus 2, Delayed-Release IDENTIFICATION A. The retention time of the major peak of the Sample Dosage Forms, Method B Procedure. solution corresponds to that of the Standard solution, as obtained in the Assay. Medium: 0.06 N hydrochloric acid; 900 ml, degassed with helium ASSAY PROCEDURE Time: 20 min Mobile phase: Transfer 0.77 g of ammonium acetate, Standard solution: 0.128 mg/ml of USP Doxycy- 0.75 g of sodium hydroxide, 0.50 g of tetrabutylam- cline Hyclate RS in Medium. Calculate the concentramonium hydrogen sulfate, and 0.40 g of edetate diso- tion, C S, in mg/ml of doxycycline, using the desigdium to a 1000-mL volumetric flask. Add 850 ml of nated potency, in µg/mg of doxycycline in USP water, and dissolve. Add 70 g of tertiary butyl alcohol Doxycycline Hyclate RS. [NOTE Sonicate if necessary with the aid of water, dilute with water to volume, and to dissolve.] adjust with acetic acid or ammonium hydroxide to a ph of 9.00 ± 0.05. test through a suitable PVDF filter of 0.45-µm pore Standard solution: 1.16 mg/ml of doxycycline hyclate size. in methanol and water (1:9). Transfer USP Doxycycline Detector: UV 346 nm Hyclate RS to a suitable volumetric flask, and add Cell: 0.1-cm quartz methanol to 10% of the final volume. Sonicate for 5 min or until dissolved. Dilute with water to volume. Protect the Standard solution from light. Calculate the concentration, C S, in mg/ml of doxycycline, using the designated potency, in µg/mg of doxycycline in USP Doxycycline Hyclate RS. Sample solution: Equivalent to 1 mg/ml of doxycy- cline in a mixture of methanol and water (1:9) from NLT 10 Tablets, crushed. Prepare the solution as follows. Weigh and crush NMT 2 Tablets at a time in a suitable mortar. Transfer a weighed portion of the powder to a suitable volumetric flask, add methanol to 10% of the final volume, and sonicate. Dilute with water to volume, sonicating as necessary. Pass through a suitable filter. Protect the Sample solution from light. Chromatographic system (See Chromatography 621, System Suitability.) Mode: LC Detector: UV 270 nm Column: 4.6-mm 25-cm; packing L21 Column temperature: 52 ± 2 Flow rate: 1 ml/min Injection volume: 15 µl Run time: 1.7 times the retention time of the doxycy- cline peak System suitability Sample: Standard solution Suitability requirements Tailing factor: NMT 2.0 Relative standard deviation: NMT 2.0% from six replicate injections doxycycline (C 22H 24N 2O 8) in the portion of Tablets taken: Result = (r U/r S) (C S/C U) 100 A U = absorbance of the Sample solution A S = absorbance of the Standard solution V = volume of Medium, 900 ml Level 1 (6 Tablets tested): No individual value is more than 30% of the labeled amount of doxycycline (C 22H 24N 2O 8) dissolved in 20 min. Level 2 (6 Tablets tested): NMT 2 individual values of the 12 tested are greater than 30% of the labeled amount of doxycycline (C 22H 24N 2O 8) in 20 min. Conduct this stage of testing on separate Tablets, selecting those that were not previously subjected to Reagents, Indicators, and Solutions Buffers); 900 ml, degassed Time: 30 min Standard solution: 0.128 mg/ml of USP Doxycycline Hyclate RS in Medium. Calculate the concentration, C S, in mg/ml of doxycycline, using the designated potency, in µg/mg of doxycycline in USP Doxycycline Hyclate RS. [NOTE Sonicate if necessary to dissolve.] test through a suitable PVDF filter of 0.45-µm pore r U = peak response from the Sample solution size. r S = peak response from the Standard solution : Determine the percentage of doxycycline (C 22H 24N 2O 8) dissolved by the procedure described for the.

2 Doxycycline Official August 1, 2017 : NLT 85% (Q) of the labeled amount of doxycycline, using the designated potency, in µg/ doxycycline (C 22H 24N 2O 8) is dissolved. mg of doxycycline in USP Doxycycline Hyclate RS. Test 2: If the product complies with this test, the labeling indicates that the product meets USP Dissolution Table 2 Test 2. Proceed as directed for Dissolution 711, Procedure, Apparatus 1 and Apparatus 2, Delayed-Release Concentration of Dosage Forms, Method B Procedure. Tablet Strength Doxycycline (mg/tablet) (mg/ml) Medium, Apparatus 1, Time, Blank, and : 75 0.1 Proceed as directed for in Test 1. 100 0.1 Standard solution: (L/900) mg/ml of USP Doxycy- 150 0.17 cline Hyclate RS in Medium. Calculate the concentration, C S, in mg/ml of doxycycline, using the desig- nated potency, in µg/mg of doxycycline in USP Doxycycline Hyclate RS. Sonicate if necessary to dissolve. Cell: 0.2 cm Cell: See Table 1. Table 1 Tablet Strength Cell Size (mg/tablet) (cm) A U = absorbance of the Sample solution 75 0.5 A S = absorbance of the Standard solution 100 0.5 150 0.2 V = volume of Medium, 900 ml Level 1 (6 Tablets tested): No individual value is : See Table 3. more than 50% of the labeled amount of doxycycline (C 22H 24N 2O 8) dissolved in 20 min. Table 3 Level 2 (6 Tablets tested): NMT 2 individual values of the 12 tested are greater than 50% of the labeled amount of doxycycline (C 22H 24N 2O 8) in 20 Tablets Tablets min. Labeled to Labeled to Number Contain 75 or Contain Conduct this stage of testing on separate Tablets, se- of Tablets 100 mg of 150 mg of lecting those that were not previously subjected to Level Tested Doxycycline Doxycycline No individual No individual value exceeds value exceeds Reagents, Indicators, and Solutions Buffers); 1000 ml, A 1 6 50% at 20 min. 30% at 20 min. degassed Average of 12 Average of 12 Apparatus 1 and : Proceed as directed for units (A 1 + A 2) units (A 1 + A 2) in Test 1. is NMT 50% at is NMT 30% at Time: 45 min 20 min, and no 20 min, and no Standard solution: (L/1000) mg/ml of USP Doxycy- individual unit individual unit cline Hyclate RS in Medium. Calculate the concentra- is greater than is greater than tion, C S, in mg/ml of doxycycline, using the desig- A 2 6 65% dissolved. 45% dissolved. nated potency, in µg/mg of doxycycline in USP Average of 24 Average of 24 Doxycycline Hyclate RS. Sonicate if necessary to units (A 1 + A 2 + units (A 1 + A 2 + dissolve. A 3) is NMT 50% A 3) is NMT 30% at 20 min, and at 20 min, and no individual no individual Detector and Cell: Proceed as directed for unit is greater unit is greater in Test 2. than 65% dis- than 45% dis- : NLT 70% (Q) of the labeled amount of A 3 12 solved. solved. doxycycline (C 22H 24N 2O 8) is dissolved. Test 3: If the product complies with this test, the label- ing indicates that the product meets USP Dissolution Conduct this stage of testing on separate Tablets, se- Test 3. Proceed as directed for Dissolution 711, Proce- lecting those that were not previously subjected to dure, Apparatus 1 and Apparatus 2, Delayed-Release Dosage Forms, Method B Procedure. Reagents, Indicators, and Solutions Buffers); 1000 ml Apparatus 1 and Time: Proceed as directed for Acid stage in Test 1. Time: 60 min Medium: 0.06 N hydrochloric acid; 900 ml Standard solution: Prepare the solutions as directed Standard solution: Prepare the solutions as directed in Table 4 from USP Doxycycline Hyclate RS in Mein Table 2 from USP Doxycycline Hyclate RS in Me- dium. Calculate the concentration, C S, in mg/ml of dium. Calculate the concentration, C S, in mg/ml of

Official August 1, 2017 Doxycycline 3 doxycycline, using the designated potency, in µg/ mg of doxycycline in USP Doxycycline Hyclate RS. V = volume of Medium, 900 ml Table 4 Level 1 (6 Tablets tested): No individual value is more than 30% of the labeled amount of doxycy- Concentration of cline (C 22H 24N 2O 8) dissolved in 20 min. Tablet Strength Doxycycline Level 2 (6 Tablets tested): NMT 2 individual values (mg/tablet) (mg/ml) of the 12 tested are greater than 30% of the la- 75 0.1 beled amount of doxycycline (C 22H 24N 2O 8) in 20 100 0.1 min. 150 0.15 Conduct this stage of testing on separate Tablets, selecting those that were not previously subjected to Cell: 0.2 cm Reagents, Indicators, and Solutions Buffers); 1000 ml, degassed Time: 30 min Standard solution: 0.1 mg/ml of doxycycline from USP Doxycycline Hyclate RS in Medium Calculate the concentration, C S, in mg/ml of doxycycline, using the des- A U = absorbance of the Sample solution ignated potency, in µg/mg of doxycycline in USP A S = absorbance of the Standard solution Doxycycline Hyclate RS. V = volume of Medium, 1000 ml : See Table 5. Table 5 Tablets Labeled to Contain A U = absorbance of the Sample solution 75 or 100 mg of Tablets Labeled to Contain A S = absorbance of the Standard solution Doxycycline 150 mg of Doxycycline NLT 80% (Q) of the labeled NLT 70% (Q) of the labeled amount of doxycycline amount of doxycycline (C 22H 24N 2O 8) is dissolved. (C 22H 24N 2O 8) is dissolved. V = volume of Medium, 1000 ml : NLT 75% (Q) of the labeled amount of Test 4: If the product complies with this test, the label- doxycycline (C 22H 24N 2O 8) is dissolved. ing indicates that the product meets USP Dissolution.Test 5: If the product complies with this test, the Test 4. Proceed as directed for Dissolution 711, Proce- labeling indicates that the product meets USP Dissoludure, Apparatus 1 and Apparatus 2, Delayed-Release tion Test 5. Proceed as directed for Dissolution 711, Dosage Forms, Method B Procedure. Procedure, Apparatus 1 and Apparatus 2, Delayed-Re- lease Dosage Forms, Method B Procedure. Medium: 0.06 N hydrochloric acid; 900 ml, degassed Medium: 0.06 N hydrochloric acid; 900 ml Apparatus 1: 100 rpm Time: 20 min Time: 20 min Standard solution: 0.1 mg/ml of doxycycline from Standard solution: 0.06 mg/ml of doxycycline from USP Doxycycline Hyclate RS in Medium. Calculate the USP Doxycycline Hyclate RS in Medium. Calculate the concentration, C S, in mg/ml of doxycycline, using concentration, C S, in mg/ml of doxycycline, using the designated potency, in µg/mg of doxycycline in the designated potency, in µg/mg of doxycycline in USP Doxycycline Hyclate RS. USP Doxycycline Hyclate RS. Cell: 0.2-cm quartz Cell: 1.0 cm A U = absorbance of the Sample solution A U = absorbance of the Sample solution A S = absorbance of the Standard solution A S = absorbance of the Standard solution

4 Doxycycline Official August 1, 2017 Standard solution: 0.02 mg/ml of doxycycline from V = volume of Medium, 900 ml the Standard stock solution. Protect the solution from : See Table 6. light. Sensitivity solution: 1 µg/ml of doxycycline from the Table 6 Standard solution. Protect the solution from light. System suitability stock solution: 0.04 mg/ml each of Number of USP Oxytetracycline Hydrochloride RS, USP Metha- Level Tablets Tested cycline Hydrochloride RS, and USP Doxycycline Related No individual value exceeds 50% Compound A RS. Protect the solution from light. A 1 6 at 20 min. System suitability solution: Transfer 5 ml of the Standard Average of 12 units (A 1 + A 2) is stock solution into a 25-mL volumetric flask. Heat NMT 50% at 20 min, and no on a steam bath for 60 min, and gently evaporate to individual unit is greater than dryness on a hot plate (partial degradation of doxycy- A 2 6 65% dissolved. cline to 4-epidoxycycline). Add 3 ml of the System suit- Average of 24 units (A 1 + A 2 + A 3) ability stock solution to the flask, and dilute with water is NMT 50% at 20 min, and no to volume. Pass through a suitable filter. Protect the individual unit is greater than solution from light. A 3 12 65% dissolved. System suitability Samples: Standard solution, Sensitivity solution, and System suitability solution Conduct this stage of testing on separate Tablets, se- Suitability requirements lecting those that were not previously subjected to Signal-to-noise ratio: NLT 10 for doxycycline, Sensi- tivity solution Resolution: NLT 1.5 between doxycycline and 6-epi- Reagents, Indicators, and Solutions Buffers); 900 ml doxycycline, System suitability solution Apparatus 1: 100 rpm Tailing factor: NMT 2.0, Standard solution Time: 30 min Relative standard deviation: NMT 5.0%, Standard Standard solution: 0.06 mg/ml of doxycycline from solution USP Doxycycline Hyclate RS in Medium. Calculate the concentration, C S, in mg/ml of doxycycline, using Samples: Sample solution and Standard solution the designated potency, in µg/mg of doxycycline in Calculate the percentage of each impurity in the por- USP Doxycycline Hyclate RS. tion of Tablets taken: Result = (r U/r S) (C S/C U) (1/F) 100 r U = peak response of each impurity from the Sample solution r S = peak response of doxycycline from the Standard solution C U = nominal concentration of doxycycline in the A U = absorbance of the Sample solution Sample A S = absorbance of the Standard solution F = relative response factor (see Table.7) (RB 1-Aug- 2017) Acceptance criteria: See Table.7. (RB 1-Aug-2017) V = volume of Medium, 900 ml Table.7 (RB 1-Aug-2017) : NLT 80% (Q) of the labeled amount of doxycycline (C 22H 24N 2O 8) is Relative Relative Acceptance dissolved. (RB 1-Aug-2017) UNIFORMITY OF DOSAGE UNITS 905 : Meet the Retention Response Criteria, requirements Name Time Factor NMT (%) IMPURITIES Oxytetracycline 0.3 1.0 0.5 4-Epidoxycycline a. 0.4 1.0 1.0 Methacycline 0.6 1.0 2.0 Change to read: 6-Epidoxycycline ORGANIC IMPURITIES (doxycycline related compound A) b. 0.7 0.86 2.0 Mobile phase, Sample solution, and Chromato- Doxycycline 1.0 graphic system: Proceed as directed in the Assay. a. (4R,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a- Standard stock solution: 1.16 mg/ml of doxycycline octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2- hyclate in methanol and water (1:9). Transfer USP naphthacenecarboxamide monohydrate. b. Doxycycline Hyclate RS to a suitable volumetric flask, (4S,4aR,5S,5aR,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12aoctahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2- and add methanol to 10% of the final volume. Soni- naphthacenecarboxamide monohydrate. cate for 5 min or until dissolved. Dilute with water to volume. Protect the solution from light. Calculate the ADDITIONAL REQUIREMENTS concentration, in mg/ml of doxycycline, using the des- ignated potency, in µg/mg of doxycycline in USP Doxycycline Hyclate RS. PACKAGING AND STORAGE: Preserve in tight, light-resistant containers. Store at controlled room temperature.

Official August 1, 2017 Doxycycline 5 LABELING: When more than one Dissolution test is given, 1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracenethe labeling states the test used only if Test 1 is not 2-carboxamide. used. C 22H 24N 2O 8 444.43 USP REFERENCE STANDARDS 11 USP Methacycline Hydrochloride RS USP Doxycycline Hyclate RS USP Oxytetracycline Hydrochloride RS USP Doxycycline Related Compound A RS 6-Epidoxycycline, or (4S,4aR,5S,5aR,6S,12aS)-4-(di- methylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-